Patients receiving rituximab maintenance and undergoing observation demonstrated similar rates of overall and disease-free survival.
Impaired ability to conduct instrumental activities of daily living and high disease risk index were associated with poorer outcomes.
Current guidelines support autologous transplantation for consolidation in transplant-eligible patients with peripheral T-cell lymphoma.
A substantial proportion of patients who received bosutinib achieved major cytogenetic response and molecular response within 1 year.
Outcome data from 222 patients with active Waldenstrom macroglobulinemia who were treated at the Mayo Clinic over 18 years were retrospectively reviewed.
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
No association was found between number of organs involved and progression-free or overall survival in patients with amyloidosis who underwent transplant.
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
When added to bortezomib, thalidomide, and dexamethasone, daratumumab was associated with higher rates of measurable disease negativity.
Intensity of induction chemotherapy was associated with measurable residual disease negativity but not overall survival.
In this meta-analysis, researchers analyzed progression-free survival outcomes for 11 treatment regimens in pairwise comparisons.
Patients with both high and standard cytogenetic risk who received daratumumab experienced increased PFS.
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Among 126 patients who entered treatment-free remission, 58 remained in remission at 192 weeks.